[
  {
    "ts": null,
    "headline": "Teva Vs. Viatris: Who Will Dominate In President Trump's America?",
    "summary": "Compare Teva vs. Viatris for long-term investment in the $613B generic drugs market.",
    "url": "https://finnhub.io/api/news?id=5c3fea24dca232640cf1a10a80af361e6c899218576f0694fd728539e8ced9b4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760703531,
      "headline": "Teva Vs. Viatris: Who Will Dominate In President Trump's America?",
      "id": 137126958,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253774892/image_1253774892.jpg?io=getty-c-w1536",
      "related": "VTRS",
      "source": "SeekingAlpha",
      "summary": "Compare Teva vs. Viatris for long-term investment in the $613B generic drugs market.",
      "url": "https://finnhub.io/api/news?id=5c3fea24dca232640cf1a10a80af361e6c899218576f0694fd728539e8ced9b4"
    }
  },
  {
    "ts": null,
    "headline": "How Recent Developments Are Reshaping the Viatris Investment Story",
    "summary": "Viatris stock has seen its Fair Value Estimate rise slightly from $11.43 to $11.88 per share, reflecting cautious optimism among analysts. This modest increase follows incremental improvements in the company's revenue growth forecast and a positive response to new product rollouts. Stay tuned to discover how you can track ongoing updates to Viatris's evolving market narrative. What Wall Street Has Been Saying ? Bullish Takeaways Needham upgraded Amphastar after the FDA approval of AMP-002...",
    "url": "https://finnhub.io/api/news?id=efda2de3c7ffacd5dd0dbb180b541a8c62018680927a1e3ad05ac3f40fff7f50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760675132,
      "headline": "How Recent Developments Are Reshaping the Viatris Investment Story",
      "id": 137122705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris stock has seen its Fair Value Estimate rise slightly from $11.43 to $11.88 per share, reflecting cautious optimism among analysts. This modest increase follows incremental improvements in the company's revenue growth forecast and a positive response to new product rollouts. Stay tuned to discover how you can track ongoing updates to Viatris's evolving market narrative. What Wall Street Has Been Saying ? Bullish Takeaways Needham upgraded Amphastar after the FDA approval of AMP-002...",
      "url": "https://finnhub.io/api/news?id=efda2de3c7ffacd5dd0dbb180b541a8c62018680927a1e3ad05ac3f40fff7f50"
    }
  }
]